# A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

> **NCT06961006** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 160 (estimated)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Intismeran autogene
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06961006
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2028-07-22
- **Final completion:** 2031-09-05
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961006, "A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06961006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*